7 Jul 2016
French drugmaker Sanofi had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus.
Sanofi is the only major drugmaker working on a vaccine against Zika, which has been linked to birth defects and neurological disorders, although more than a dozen smaller biotech firms and other groups are also active in the field.
The tie-up with the Walter Reed Army Institute of Research (WRAIR) in the United States gives Sanofi access to a promising new vaccine, made from inactivated virus, that has already produced impressive results in mice. Sanofi is expecting to stat clinical trail from October onwards.
Sanofi is working on developing Zika vaccine based on its own know-how in battling established mosquito-borne diseases such as dengue, Japanese encephalitis and yellow fever.